Leukemia study restores silenced gene in mice. Could it point to new treatments for humans?
Reactivation of the silenced tumor‑suppressor gene ZBTB7A in acute myeloid leukemia via inhibition of KDM4 enzymes reduces leukemia burden in mice without harming normal blood cells.
The study demonstrates that restoring expression of the tumor‑suppressor gene ZBTB7A by inhibiting KDM4 enzymes in AML cells reduces leukemia burden in mice, suggesting a new epigenetic therapeutic strategy distinct from conventional chemotherapy.
This provides a potential epigenetic therapeutic approach that could improve outcomes for AML patients by avoiding harsh chemotherapy and promoting differentiation of leukemia cells, potentially reducing toxicity to normal blood cells.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Extensive-stage Small Cell Lung Cancer - Gallipoli Medical Research
- EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy
- Treatment of Small‑Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
- Cancer's protective shield: Blocking a signaling pathway could make small cell lung tumors visible to T cells